TY - JOUR
T1 - Molecular biomarkers in the context of focal therapy for prostate cancer
T2 - recommendations of a Delphi Consensus from the Focal Therapy Society
AU - Marra, Giancarlo
AU - Laguna, Maria Pilar
AU - Walz, Jochen
AU - Pavlovich, Christian P
AU - Bianco, Fernando
AU - Gregg, Justin
AU - Lebastchi, Amir H
AU - Lepor, Herbert
AU - Macek, Petr
AU - Rais-Bahrami, Soroush
AU - Robertson, Cary
AU - Rukstalis, Daniel
AU - Salomon, Georg
AU - Ukimura, Osamu
AU - Abreu, Andre L
AU - Barbe, Yann
AU - Cathelineau, Xavier
AU - Gandaglia, Giorgio
AU - George, Arvin K
AU - Rivas, Juan Gomez
AU - T Gupta, Rajan
AU - Lawrentschuk, Nathan
AU - Kasivisvanathan, Veeru
AU - Lomas, Derek
AU - Malavaud, Bernard
AU - Margolis, Daniel
AU - Matsuoka, Yoh
AU - Mehralivand, Sherif
AU - Moschini, Marco
AU - Oderda, Marco
AU - Orabi, Hazem
AU - Rastinehad, Ardeshir R
AU - Remzi, Mesut
AU - Schulman, Ariel
AU - Shin, Toshitaka
AU - Shiraishi, Takumi
AU - Sidana, Abhinav
AU - Shoji, Sunao
AU - Stabile, Armando
AU - Valerio, Massimo
AU - Tammisetti, Varaha S
AU - Tan, Wei Phin
AU - Van Den Bos, Willemien
AU - Villers, Arnaud
AU - Willemse, Peter-Paul
AU - de la Rosette, Jean
AU - Polascik, Thomas
AU - Sanchez-Salas, Rafael
PY - 2022/10
Y1 - 2022/10
N2 - BACKGROUND: Focal therapy (FT) for prostate cancer (PCa) is promising. However, long-term oncological results are awaited and there is no consensus on follow-up strategies. Molecular biomarkers (MB) may be useful in selecting, treating and following up men undergoing FT, though there is limited evidence in this field to guide practice. We aimed to conduct a consensus meeting, endorsed by the Focal Therapy Society, amongst a large group of experts, to understand the potential utility of MB in FT for localized PCa.METHODS: A 38-item questionnaire was built following a literature search. The authors then performed three rounds of a Delphi Consensus using DelphiManager, using the GRADE grid scoring system, followed by a face-to-face expert meeting. Three areas of interest were identified and covered concerning MB for FT, 1) the current/present role; 2) the potential/future role; 3) the recommended features for future studies. Consensus was defined using a 70% agreement threshold.RESULTS: Of 95 invited experts, 42 (44.2%) completed the three Delphi rounds. Twenty-four items reached a consensus and they were then approved at the meeting involving (N.=15) experts. Fourteen items reached a consensus on uncertainty, or they did not reach a consensus. They were re-discussed, resulting in a consensus (N.=3), a consensus on a partial agreement (N.=1), and a consensus on uncertainty (N.=10). A final list of statements were derived from the approved and discussed items, with the addition of three generated statements, to provide guidance regarding MB in the context of FT for localized PCa. Research efforts in this field should be considered a priority.CONCLUSIONS: The present study detailed an initial consensus on the use of MB in FT for PCa. This is until evidence becomes available on the subject.
AB - BACKGROUND: Focal therapy (FT) for prostate cancer (PCa) is promising. However, long-term oncological results are awaited and there is no consensus on follow-up strategies. Molecular biomarkers (MB) may be useful in selecting, treating and following up men undergoing FT, though there is limited evidence in this field to guide practice. We aimed to conduct a consensus meeting, endorsed by the Focal Therapy Society, amongst a large group of experts, to understand the potential utility of MB in FT for localized PCa.METHODS: A 38-item questionnaire was built following a literature search. The authors then performed three rounds of a Delphi Consensus using DelphiManager, using the GRADE grid scoring system, followed by a face-to-face expert meeting. Three areas of interest were identified and covered concerning MB for FT, 1) the current/present role; 2) the potential/future role; 3) the recommended features for future studies. Consensus was defined using a 70% agreement threshold.RESULTS: Of 95 invited experts, 42 (44.2%) completed the three Delphi rounds. Twenty-four items reached a consensus and they were then approved at the meeting involving (N.=15) experts. Fourteen items reached a consensus on uncertainty, or they did not reach a consensus. They were re-discussed, resulting in a consensus (N.=3), a consensus on a partial agreement (N.=1), and a consensus on uncertainty (N.=10). A final list of statements were derived from the approved and discussed items, with the addition of three generated statements, to provide guidance regarding MB in the context of FT for localized PCa. Research efforts in this field should be considered a priority.CONCLUSIONS: The present study detailed an initial consensus on the use of MB in FT for PCa. This is until evidence becomes available on the subject.
KW - Biomarkers
KW - Consensus
KW - Delphi Technique
KW - Humans
KW - Male
KW - Prostatic Neoplasms/diagnosis
KW - Surveys and Questionnaires
U2 - 10.23736/S0393-2249.20.04160-0
DO - 10.23736/S0393-2249.20.04160-0
M3 - Article
C2 - 33439577
SN - 0393-2249
VL - 74
SP - 581
EP - 589
JO - Minerva Urologica e Nefrologica
JF - Minerva Urologica e Nefrologica
IS - 5
ER -